TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Granules India Limited ( (IN:GRANULES) ) has issued an update.
Granules India Limited has inaugurated two new Centres of Excellence at IIT Hyderabad’s Technology Research Park, aimed at bolstering its R&D capabilities. The Ascelis Center of Excellence for Peptide Development and Characterization will focus on cosmetic, therapeutic, and pharmaceutical peptides, enhancing the company’s global peptide offerings. Meanwhile, the Granules Center of Excellence for Particle Engineering will advance research in polymorphs, material science, and novel drug delivery systems, supporting the creation of proprietary technologies for regulated markets. These initiatives are expected to strengthen Granules India’s competitive edge in pharmaceutical innovation and deliver significant value to its partners and patients worldwide.
More about Granules India Limited
Granules India Limited operates in the pharmaceutical industry, focusing on the development and production of active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. The company is known for its integrated business model and global market presence.
Average Trading Volume: 47,039
Technical Sentiment Signal: Strong Buy
Current Market Cap: 135B INR
For detailed information about GRANULES stock, go to TipRanks’ Stock Analysis page.